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We conducted a genomewide screen for prostate cancer–susceptibility genes on the basis of data from 98 families
from the United States and Canada that had three or more verified diagnoses of prostate cancer among first- and
second-degree relatives. We found a statistically significant excess of markers for which affected relatives exhibited
modest amounts of excess allele-sharing; however, no single chromosomal region contained markers with excess
allele-sharing of sufficient magnitude to indicate unequivocal evidence of linkage. Positive linkage signals of nominal
statistical significance were found in two regions (5p-q and 12p) that have been identified as weakly positive in
other data sets and in region 19p, which has not been identified previously. All these signals were considerably
stronger for analyses restricted to families with mean age at onset below the median than for analyses of families
with mean age at onset above the median. The data provided little support for any of the putative prostate
cancer–susceptibility genes identified in other linkage studies.
Introduction
Prostate cancer (MIM 176807) is the most common
noncutaneous malignancy among North American men:
∼198,100 men in the United States will be diagnosed
with the disease during the year 2001, and ∼31,500 men
will die of it (Greenlee et al. 2001). Although the ag-
gregation of prostate cancer in some families is widely
recognized, the genetic basis for inherited susceptibility
is poorly understood. Data from many studies suggest
that men who have a first-degree relative with prostate
cancer are two to three times more likely to develop the
disease than men in the general population (Woolf 1960;
Cannon et al. 1982; Meikle and Stanish 1982; Steinberg
et al. 1990; Spitz et al. 1991; Carter et al. 1992; Goldgar
et al. 1994; Whittemore et al. 1995). The estimated
magnitude of this relative risk does not appear to differ
across three racial/ethnic groups (African American,
white, and Asian American), despite large differences in
incidence across these groups (Whittemore et al. 1995).
Moreover, the risk appears to increase with number of
affected first-degree relatives (Steinberg et al. 1990).
Received February 15, 2001; accepted for publication May 11,
2001; electronically published June 12, 2001.
Address for correspondence and reprints: Alice S. Whittemore,
Ph.D., Stanford University School of Medicine, Department of Health
Research and Policy, Redwood Building, Room T204, Stanford, CA
94305-5405. E-mail: alicesw@stanford.edu
 2001 by The American Society of Human Genetics. All rights reserved.
0002-9297/2001/6901-0016$02.00
Further support for inherited prostate cancer suscep-
tibility comes from data suggesting autosomal dominant
inheritance within some families (Carter et al. 1992;
Gronberg et al. 1997; Schaid et al. 1998), as well as
evidence of linkage of the disease to regions on chro-
mosome 1 (Smith et al. 1996; Cooney et al. 1997; Hsieh
et al. 1997, Berthon et al. 1998; Gibbs et al. 1999b;
Neuhausen 1999; Xu 2000), chromosome 17 (Rebbeck
et al. 2000; Tavtigian et al. 2001) and chromosome 20
(Berry et al. 2000a). There also are data implicating
specific genes or regions on the X chromosome. For
example, the androgen receptor gene at Xq12 has been
studied extensively for its relation to prostate cancer
risk. In particular, specific alleles of two trinucleotide
repeats (a polyglutamine repeat and a polyglycine re-
peat) within this gene have been associated with altered
prostate cancer incidence (Giovannucci et al. 1997; In-
gles et al. 1997; Stanford et al. 1997; Platz et al. 1998)
and progression (Eeles 1999). Moreover, a linkage anal-
ysis of combined data from the United States, Finland,
and Sweden (Xu et al. 1998) revealed evidence of a
prostate cancer–susceptibility gene on Xq27-28, ∼50
cM from the androgen receptor gene. Evidence sup-
porting this linkage has been provided by Lange et al.
(1999).
However, none of these linkage results has been con-
firmed consistently (McIndoe et al. 1997; Eeles et al.
1998; Whittemore et al. 1999; Berry 2000b; Bock 2001;
Vesprini et al. 2001; Xu et al. 2001). Thus, despite these
provocative clues, the genetic causes of prostate cancer
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Table 1
Characteristics of 98 Families in the United States and Canada
That Contain Three or More Verified Prostate Cancer Cases among
First- or Second-Degree Relatives, by Mean Age at Diagnosis
CHARACTERISTIC
MEAN AGE AT
DIAGNOSIS
!66.5
Years
(N p 49)
66.5
Years
(N p 49)
ALL
FAMILIES
(N p 98)
Mean no. of reported prostate
cancer cases per family 3.7 3.6 3.7
Percent of reported cases verifieda 92.8 91.6 92.2
Mean no. of affected and geno-
typed cases per family 2.7 2.5 2.6
Percent nonwhite 16.3 14.3 15.3
a Verified by medical record or death certificate.
remain unclear. Like other diseases with late ages at
onset, prostate cancer presents formidable obstacles to
mapping susceptibility loci: parents of affected men are
seldom available for genotyping, and offspring are usu-
ally too young for assessment of phenotype. Numbers
of informative family members are further restricted by
the sex-limited nature of the disease. Moreover it has
become increasingly probable that prostate cancer is a
genetically heterogeneous disease. Given this likely het-
erogeneity, it is important to evaluate suggestive leads
with several sets of independent families that contain
multiple cases of the disease. Accordingly, we present
here the results of a genome screen for allele sharing at
382 markers among 98 families from the United States
and Canada that contain three or more members di-
agnosed with prostate cancer.
Families and Methods
Families
The analysis is based on 98 unrelated families, each
containing three or more medically verified diagnoses of
prostate cancer among first- or second-degree relatives.
The families were identified from a multiethnic case-
control study conducted in Hawaii, Los Angeles, San
Francisco, and Vancouver (Whittemore et al. 1995), as
well as from screens of the British Columbia Cancer
Registry and the San Francisco–Oakland Cancer Reg-
istry and from publicity in the San Jose Mercury News.
Eighty-two of these families fulfilled one or more of the
proposed criteria for families in which prostate cancer
is likely to be hereditary (i.e., three or more affected
individuals within one nuclear family, affected individ-
uals in three generations, and/or two or more individuals
affected at !55 years of age). Seven families were African
American, five were Japanese American, and three were
Chinese American.
Table 1 summarizes pertinent characteristics of these
98 families. The mean number of affected and genotyped
men per family was 2.6 (range 2–5 men), and the mean
age at diagnosis of all affected men was 66.5 years (66.9
years in white families, 63.5 years in African American
families, and 69.2 years in Asian American families).We
were able to verify 331 (92.2%) of the 359 reported
cases of prostate cancer in the families. We did not at-
tempt to obtain systematic information about the stages
and grades of the cancers in affected men.
Genotyping
Genotyping was performed by the NHLBI Mamma-
lian Genotyping Service at the Center for Medical Ge-
netics, Marshfield Medical Research Foundation. DNA
samples from family members were typed at 382 auto-
somal and X-linked markers in the Weber screening set
9 (Yuan et al. 1997). Average marker heterozygositywas
77%, and average spacing between markers on sex-
equal maps was 9 cM (Broman et al. 1998). Genotyping
was implemented using an ABI 377 sequencer to read
fluorescence-labeled primers for PCR products. If a
marker genotype was missing or ambiguous for an in-
dividual, we used the radiolabelingmethod to retype that
marker for that person. To insure interlaboratory com-
parability, we also retyped the marker in question for at
least one relative of the individual and resolved any dis-
crepancies. We genotyped a total of 55 other markers
in regions containing markers with evidence suggestive
of linkage, either in the present data or in data from
other linkage studies. We selected the additional markers
from the genome database to achieve ∼2–4 cM density
in the regions of interest. PCR products of these markers
were fractionated using the LiCor Gene Reader 4200
and the SAGA software.
Statistical Methods
Single-point and multipoint parametric LOD scores,
nonparametric Z scores and Kong and Cox (KC) Z
scores and one-tailed P values were obtained using the
software GENEHUNTER-PLUS (Kruglyak et al. 1996;
Kong and Cox 1997). For the parametric analyses, we
assumed an autosomal dominant mode of inheritance of
a disease-susceptibility allele with a frequency of .003
and with penetrances as estimated in the segregation
analysis of Carter et al. (1992). For the nonparametric
analyses, we report KC Z scores based on the linear
model option, the ALL scoring function, and equal
weights for each family. Results from the parametric and
nonparametric analyses were qualitatively similar. Thus,
for brevity, we report only the nonparametric statistics.
We estimated marker allele frequencies in family foun-
ders, using the software FASTLINK (Cottingham et al.
1993; Schaffer et al. 1994).
Genetic analysis revealed that one pair of twins was
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Figure 1 Blackened circles show single-point KC Z scores for
the 382 markers in the Weber screening set 9, plotted against F1 (R/
382), where R is the ordered rank of the Z score, and F is the standard
Gaussian cumulative distribution function. The curve contains only
the points corresponding to Z scores with ranks 191–381. Under the
null hypothesis of no linkage, the curve should lie on the line .yp x
Also shown are 90% (dotted line) and 95% (dashed line) confidence
intervals, based on 2,000 replications of data for 382 independent
draws from a 50:50 mixture of the distribution with all its mass at
zero and the distribution of the absolute value of a standard Gaussian
variable.
monozygous; we therefore removed one twin from all
analyses.
Results
Figure 1 shows the distribution of single-point KC Z
scores for the 382 markers in the Weber screening set
9. Each Z score is plotted as a function of the value
F1(R/382), where R is its rank in order of increasing
size, and F is the standard Gaussian cumulative distri-
bution function. Under the null hypothesis of no linkage,
this curve should fit the line . As evident in theyp x
figure, the curve lies above the line for all but twoyp x
data points. This indicates that the entire distribution of
KC Z scores is shifted upward. This shift results, in part,
from the fact that 262 (69%) of theZ scores are positive,
in contrast to the number (382/2p 191) expected under
the null hypothesis. There also is an excess of Z scores
with values of 2.1–2.5. Also shown in figure 1 are 90%
and 95% confidence intervals for the curve. These are
based on 2,000 replications of 382 independent draws
from the null distribution of Z scores, which is approx-
imately a 50:50 mixture of the distribution with all its
mass at zero and the distribution of the absolute value
of a standard Gaussian variable. The nominally signif-
icant Z scores (i.e., those 11.96) decrease within these
bounds, indicating that they do not meet the criteria for
statistical significance in a 382-marker screen. However,
the excess of positive Z scores evident in the figure is
statistically significant ( ). This excess indicatesP ! .01
the presence of modest amounts of excess allele sharing
among relatives at many different loci in the genome.
Figure 2 shows multipoint and single-point KC Z
scores for all ( ) markers on all 22 au-382 55p 437
tosomes and on the X chromosome. Regions with mul-
tipoint Z scores 1.96 are seen on chromosomes 5q,
12p, and 19p. In addition, single-point Z scores 12.0
without correspondingly high multipoint Z scores
are evident on chromosome 15q (D15S642, 122 cM
from 15pter [KC ]), on chromosome 17pZp 2.67
(D17S1308, 1 cM from 17pter [KC ], andZp 2.39
D17S1303, 24 cM from 17pter [KC ]), andZp 2.44
on the X chromosome (DXS2390, 195 cM from pterX;
KC ). The X chromosome marker DXS2390Zp 2.57
is 1 cM distal to marker DXS1113, which showed
strong evidence of linkage in the data of Xu et al.
(1998). We also obtained a single-point KC Z score of
1.93 for the marker D1S2883, which lies in the region
1q24-25 identified by Smith et al. (1996). Thus, as we
noted previously (Hsieh et al. 1997), the single-point
analysis provides weak support for the existence of a
susceptibility gene in that region. The lack of support
for these loci from the multipoint analysis may indicate
power loss due to misspecification of the marker loca-
tions (Halpern and Whittemore 1999).
Among the pairs of adjacent markers in the Weber
screening set 9, we found only one in which both mark-
ers had multipoint KC Z scores 11.645 (the cutoff for
nominal statistical significance based on a single
marker). The two markers in this pair are 11 cM apart
in region 19p: marker D19S591 (multipoint KC Zp
) and D19S1034 (multipoint KC2.57p 2.38 Zp
). Among all 437 markers (including the2.57p 2.49
additional 55 from suggestive regions), the number of
such pairs was 10: one pair in region 5q, three pairs in
region 12p, and six pairs in region 19p. The specific
markers and their multipoint KC Z scores are shown
in table 2.
To further investigate the suggestive evidence of link-
age in regions 5q, 12p, and 19p, we subdivided the
families according to numbers of affected men (3 vs.
4) and according to mean age at prostate cancer di-
agnosis among the affected men (!66.5 years vs.66.5
years), where 66.5 years was the median value for all
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Figure 2 Single-point (#) and multipoint () KC Z scores for the 437 markers genotyped in 98 families that contain three or more
members with prostate cancer.
families. Table 2 shows multipoint KC Z scores for each
of these subgroups and for all families combined. Vir-
tually without exception, the Z scores are higher for
families whose affected members were diagnosed at
early ages than for those whose members were diag-
nosed at later ages. Because cancers due to mutations
of susceptibility genes tend to occur at earlier ages than
do sporadic cancers, these observations lend support to
the possibility that these regions may contain suscep-
tibility loci. For regions 5q and 12p, but not 19p, the
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Table 2
Multipoint KC Z Scores for Regions Containing a Marker with Multipoint KC Z Score 11.96, According to Mean Age at Diagnosis and
Number of Affected Family Members
REGION AND MARKER
POSITION
(cM)
Z SCORES IN FAMILIES WITH
MEAN AGE AT DIAGNOSIS OF Z SCORES IN FAMILIES WITH
OVERALL
Z SCORES
(N p 98)
!66.5 Years
(N p 49)
66.5 Years
(N p 49)
4 Men
Affected
(N p 39)
3 Men
Affected
(N p 59)
5p13.3-5q13.1
D5S2076 62 1.21 .35 .44 1.07 1.12
D5S407 65 1.15 .11 .68 .67 .94
D5S2507 67 .96 .44 .44 .94 1.02
D5S2500 69 1.54 1.14 1.77 1.12 1.92
D5S2858 70 1.54 1.25 2.04 1.02 1.98
D5S647 74 1.45 0 1.82 0 1.01
D5S629 76 1.29 .21 1.53 .36 1.14
D5S1988 78 .84 .02 1.06 .02 .64
12p13.3-12.3
D12S1694 3 1.18 1.47 1.71 .97 1.87
D12S372 6 2.07 1.86 2.41 1.57 2.78
D12S1725 10 1.97 1.12 2.30 .89 2.20
D12S93 13 2.08 .68 2.04 .85 2.00
D12S2395 18 2.18 0 2.18 .22 1.60
D12S391 26 1.06 .60 1.52 .25 1.20
D12S373 36 1.13 0 1.97 0 .70
19p13.3
D19S883 6 1.25 .50 .66 1.05 1.24
D19S878 7 1.85 .56 .91 1.45 1.71
D19S591 10 2.39 .99 1.38 1.95 2.38
D19S209 11 2.65 .54 1.41 1.75 2.21
D19S894 16 2.67 1.38 1.71 2.33 2.87
D19S177 20 2.81 .80 1.73 1.89 2.54
D19S1034 21 2.68 .85 1.68 1.87 2.49
D19S427 22 2.13 .83 .94 1.88 2.08
Table 3
KC Z Scores for Region Xq25-27 According to Presence or Absence
of Evidence for Male:Male Transmission (MMT)
MARKER
POSITION
(cM)
SCORES IN
FAMILIES
WITHOUT
MMT
(Np 6)
SCORES IN
FAMILIES
WITH
MMT
(N p 42)
OVERALL
Z SCORES
(N p 98)
Z1 ZM Z1 ZM Z1 ZM
GATA165B12 133 2.10 .33 .55 2.06 1.79 1.58
DXS1047 143 1.02 .53 .70 1.23 1.19 1.19
DXS2390 154 2.07 .83 1.62 .59 2.57 1.02
DXS6751 158 .07 .60 .47 0 .39 .35
DXS8106 163 0 .55 1.08 0 .38 .00
NOTE.—Z1 p single-point KC Z score; ZM p multipoint KC Z
score.
Z scores tend to be higher for families with four or
more affected men than for those with only three af-
fected men.
We also evaluated evidence of linkage to markers on
the X chromosome after classifying the families ac-
cording to presence or absence of evidence of male:male
transmission (MMT), as defined by Xu et al. (1998).
Table 3 shows single-point and multipoint KC Z scores
in the region Xq25-27 for the two subgroups of families
and for all families. The single-point Z scores at two of
the markers were elevated for families without evidence
ofMMT. However, the multipointZ scores in the region
were unremarkable.
Table 4 summarizes the strength of evidence in the
present data for chromosomal regions identified by
other linkage analyses as possibly containing a prostate
cancer–susceptibility gene. The table shows multipoint
KC Z scores for markers within 10 cM of those iden-
tified by others as having a Z score 11.96 or a LOD
score 10.834. The multipoint Z scores shown in table
4 provide no support for any of the three regions iden-
tified on chromosome 1 (1p36, 1q24-25, or 1q42-43).
Indeed, only two of the regions identified by others are
supported by the present data: region 5p12-q13 (iden-
tified by Smith et al. [1996]), and region 12p13-14
(identified by Suarez et al. [2000]). There is need for
further evaluation of these two regions in additional
linkage data.
Because of the likely genetic heterogeneity, it is pos-
Table 4
Multipoint KC Z Scores for Markers in Regions Reported to Contain Possible Prostate
Cancer–Susceptibility Genes
Region Marker
Position
(cM) Reference
Nearest
Marker(s)
Position
(cM)
Multipoint
KC Z
1p32-41 D1S1656 245 Gibbs et al. 1999b D1S549 240 .28
1q24-25 D1S218 191 Smith et al. 1996 D1S452 189 0
D1S1589 192 0
D1S212 194 0
1q42-43 D1S235 255 Smith et al. 1996 D1S3462 247 .14
D1S235 255 0
D1S2785 266 Berthon et al. 1998 D1S547 268 0
D1S1609 275 0
2q37-38 D2S2228 224 Suarez et al. 2000 D2S1363 227 0
4q26-31 D4S430 126 Smith et al. 1996 D4S2623 114 0
D4S2394 130 0
D4S1644 143 .64
5p12-q13 D5S407 65 Smith et al. 1996 D5S2076 62 1.12
D5S407 65 .94
D5S2507 67 1.02
D5S2500 69 1.92
D5S2858 70 1.98
D5S647 74 1.01
5q31-33 D5S1480 147 Witte et al. 2000 D5S1480 147 1.33
D5S820 160 D5S820 160 1.47
7p21 D7S507 29 Smith et al. 1996 D7S3051 29 .23
7q32 D7S3061 128 Witte et al. 2000 D7S3061 128 0
D7S1804 137 D7S1804 137 0
8q21 D8S2324 94 Gibbs et al. 2000 D8S1136 82 .87
D8S2324 94 0
9p22-23 D9S925 32 Gibbs et al. 2000 D9S921 22 .39
D9S925 32 .25
10q25-26 D10S1223 156 Gibbs et al. 2000 D10S1213 148 .61
D10S1248 165 0
11p13-15 ATA34E08 33 Gibbs et al. 2000 ATA34E08 33 0
12p13-14 D12S1685 8 Suarez et al. 2000 D12S1694 3 1.87
D12S372 6 2.78
D12S1725 10 2.20
D12S93 13 2.00
12q24-25 D12S1045 161 Gibbs et al. 2000 D12S1045 161 .20
D12S392 166 0
13q32 D13S159 79 Smith et al. 1996 D13S793 76 0
D13S779 83 0
14q24 D14S588 76 Gibbs et al. 2000 D14S588 76 .38
15q13 D15S1010 24 Suarez et al. 2000 D15S165 20 .14
16p13-14 D16S748 23 Gibbs et al. 2000 D16S748 23 0
16p13 D16S3103 32 Suarez et al. 2000 D16S748 23 0
D16S764 30 0
16q23-24 D16S3096 99 Suarez et al. 2000 D16S2624 88 0
D16S516 100 0
17P D17S947 32 Tavtigian et al. 2001 D17S947 32 .04
19q12 D19S433 52 Witte et al. 2000 D19S433 52 .22
D19S245 59 .61
20q13 D20S196 75 Berry et al. 2000a D20S480 80 0
Xq27-28 DXS1193 175 Smith et al. 1996;
Xu et al. 1998 DXS1193 175 0
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Table 5
Pearson-Product Correlation Coefficients for Family-Specific Multipoint Nonparametric Z Scores
Coefficient at
Marker Region D1S549 D1S452 D1S235 D5S2500 D12S372 D19S894 D20S480
D1S549 1p32-41 1.0 .25a .51b .12 .11 .18 .19
D1S452 1q24-25 1.0 .20a .22a .20a .15 .15
D1S235 1q42-43 1.0 .05 .20a .21a .11
D5S2500 5p12-q13 1.0 .10 .13 .03
D12S372 12p13-14 1.0 .01 .08
D19S894 19p13 1.0 .01
D20S480 20q13 1.0
a P !.05
b P !.01
sible that families with elevated Z scores in one can-
didate region have only slightly positive, or even neg-
ative,Z scores in other regions. In addition, if mutations
at two different loci interact epistatically to cause dis-
ease, restriction of analysis to families with positive Z
scores in one candidate region may substantially elevate
the overall Z score at another candidate region (Cox et
al. 1999). To investigate these possibilities, we examined
correlations between family-specific Z scores in regions
that may harbor a susceptibility locus. Table 5 shows
correlation coefficients for family-specific nonparame-
tric multipoint Z scores at representative markers in
regions 1q24-25, 1q42-43, 5p12-q13, 12p13-14,
19p13, and 20q13. Z scores at the markers on chro-
mosome 12p are negatively correlated with those in all
the other regions. This suggests that families with ele-
vated Z scores in this region are not segregating dele-
terious alleles at other candidate loci. Separate analysis
of the two subgroups of families determined by mean
ages at prostate cancer diagnosis produced similar cor-
relation coefficients (data not shown). We recalculated
the KC multipoint Z score at marker D1S452 in the
HPC1 region 1q24-25, weighting each family according
to its Z score at D12S372, as proposed by Cox et al.
(1999). Specifically, families with positive Z scores at
D12S372 were excluded from analysis, and families
with negative Z scores were weighted in proportion to
the absolute values of their Z scores. This analysis did
not increase the Z score at D1S452, as would be ex-
pected if one subset of families were linked to D1S452,
with the remaining families linked to D12S372. Con-
versely, the multipointZ score at D12S372with families
weighted according to their Z scores at D1S452 also
failed to support such a partition of families. Further-
more, we did not find any strong indications from sim-
ilar analyses at other pairs of loci of statistically sig-
nificant positive or negative correlations (table 5).
Discussion
We have reported the results of a linkage screen, using
a total of 437 polymorphic markers, of 98 families with
multiple cases of prostate cancer. Although four chro-
mosomal regions showed suggestive evidence of linkage,
no single region showed excess allele sharing of a mag-
nitude sufficient to exclude chance as an explanation
(Kruglyak and Lander 1996). In contrast, the number
of loci exhibiting small-to-moderate amounts of excess
allele sharing was significantly greater than that expected
by chance. This extensive excess allele sharing suggests
the presence of many susceptibility loci, each having
small to moderate effect, and acting either additively or
synergistically to increase risk. The possibility of syn-
ergism among two or more genes is supported by pros-
tate cancer occurrence in the co-twins of World War II
veterans from the United States who had prostate cancer
(Page et al. 1997). The disease was approximately four
times more prevalent in monozygous (MZ) co-twins
than in dizygous (DZ) co-twins of the affected men. This
fourfold increase is larger than that expected under a
model in which one or more genes act independently to
increase risk. Instead, it suggests the synergistic action
of two or more genes, all of whose deleterious alleles
are more likely to be shared by an MZ co-twin than a
DZ one.
We have summarized the strength of support in these
data for chromosomal regions identified in previous
linkage studies of prostate cancer. Overall, the level of
support is weak. Three regions on chromosome 1 have
been implicated as containing a potential prostate
cancer–susceptibility gene: 1p36, 1q24-25, and 1q42-
43. On the basis of 70 multiple-case families in a ge-
nomewide screen and 71 additional families, Gibbs et
al. (1999b) presented evidence of a rare susceptibility
locus at 1p36. This region appears to be important only
for families with primary brain cancer: the authors
found a LOD score of 3.22 in 12 of the families that
contained at least one individual with primary brain
cancer. However, an analysis of 13 families with pros-
tate cancer that also included one or more member with
a diagnosis of brain cancer did not find evidence of
linkage in this region (Berry et al. 2000b). Cancers of
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the CNS were reported in only six of the families in-
cluded in the present analysis, and wewere able to verify
only one of them as being a primary cancer of the brain.
Thus, we have little power to confirm or refute the
linkage.
Smith et al. (1996) presented evidence, obtained from
91 families from the United States and Sweden that
included multiple cases of prostate cancer, of a locus in
region 1q24-25 (designated “HPC1”). A subsequent
reanalysis of an expanded collection of these families
suggested that the strongest linkage evidence derived
from families with early mean ages at onset (Gronberg
et al. 1999). This finding has received modest support
from the following three studies. (1) Cooney et al.
(1997) reported a nonparametric Z score of 1.58
( ) at D1S466 that was based on analysis of 59Pp .06
multiplex families. (2) We reported equivocal evidence
of linkage (Hsieh et al. 1997) that was based on a subset
of 92 of the 98 families described here; however, other
data sets have failed to exhibit linkage in this region
(McIndoe et al. 1997; Berthon et al. 1998; Eeles et al.
1998; Suarez et al. 2000). (3) A combined analysis of
772 families with multiple cases of prostate cancer that
was conducted by the International Consortium for
Prostate Cancer Genetics (Xu 2000) found weak evi-
dence overall, suggesting that HPC1 may account for,
at most, a small fraction of families with multiple cases
of prostate cancer. We did not find additional support
from the slightly expanded collection of the present fam-
ilies, even in that subset of families ( ) with earlyNp 21
ages at onset and with evidence of MMT. This absence
of additional support suggests that, if there is a prostate
cancer–susceptibility gene in this region, it segregates
only in a small subset of families with multiple cases of
prostate cancer.
On the basis of findings in 47 French and German
families, Berthon et al. (1998) reported a nonparametric
Z score of 3.1 for marker D1S2785 in region 1q42-43.
This finding is interesting because, although D1S2785
is considerably distal to the region 1q24-25 identified
by Smith et al. (1996), this marker is only 14 cM away
from D1S235, which also produced an elevated Z score
in the scan by Smith et al. (1996). However, the mul-
tipoint KC Z scores for all three of the nearest markers
in the present analysis were negative, as we have re-
ported elsewhere (Whittemore et al. 1998). Moreover,
Gibbs et al. (1999a) reported negative LOD scores for
four markers in this region.
In addition to these three regions on chromosome 1,
linkage studies have implicated regions on chromo-
somes 16 (Gibbs et al. 2000; Suarez et al. 2000), 17
(Tavtigian et al. 2001), and 20 (Berry et al. 2000a).
Using data from 162 North American families that con-
tained three or more members with prostate cancer,
Berry et al. (2000a) reported evidence of linkage to re-
gion 20q13, with a maximum multipoint nonparame-
tric Z score of 3.02 at D20S887 and a maximum single-
point LOD score of 2.69 for marker D20S196.
However, the linkage study of Bock et al. (2001) did
not provide statistically significant support for this lo-
cus. Moreover, in the present data, none of the multi-
point KC Z scores for markers near these regions were
elevated. Similarly, these data did not show strong ev-
idence of linkage to markers near the gene HPC2 iden-
tified by Tavtigian et al. (2001), and reports of altered
prostate cancer risk associated with two relatively com-
mon polymorphisms of these genes have been equivocal
(Rebbeck et al. 2000; Xu et al. 2001; Vesprini et al.
2001).
Instead, we found elevated KC Z scores in three
regions: 5p13.3-5q13.1, 12p13.3-12.3, and 19p13.3.
There is modest evidence suggesting that chromosome
5q may harbor a prostate cancer–susceptibility gene
(e.g., reports by Lin et al. [2000] and Bova et al. [1996]).
Nonstatistically significant LOD scores of ∼1.0 were
noted in the centromeric region 5p13.3–5q13.1 among
the 91 families from the United States and Sweden
described by Smith et al. (1996). The long arm of
chromosome 5 contains the gene encoding a-catenin
(CTNNAI), which is part of the E-cahedrin pathway
that has been implicated extensively in prostate carci-
nogenesis. Associations between LOH on 5q and pros-
tate cancer stage at diagnosis have been noted (Cher et
al. 1996, 1998; Cunningham et al. 1996; Latil et al.
1996; Brothman et al. 1997; Dong et al. 1997; Ozen et
al. 1998).
We found a large region on chromosome 12p con-
taining markers with elevated Z scores. Moreover, the
elevated Z scores were restricted to families in which
prostate cancers were diagnosed when affected family
members were relatively young. Suarez et al. (2000) also
found elevated KC Z scores in this region, and these
authors found stronger signals when analysis was re-
stricted to families with relatively early ages at onset.
Kibel et al. (1998, 1999, 2000) used representational
difference analysis to identify 12p12-13 as a region of
frequent deletion in prostate cancer (see also Azar et al.
[1997]).
In the present data, the strongest evidence of linkage
occurred in the region 19p. The evidence was consis-
tently stronger when analysis was restricted to families
in which prostate cancers were diagnosed when affected
family members were relatively young, compared with
families that had older ages at onset. To our knowledge,
this region has not been reported by other investigators
as harboring a putative susceptibility locus, and it war-
rants further investigation.
In conclusion, in these 98 families with three or more
confirmed cases of prostate cancer, we found statistically
significant evidence of excess allele sharing among af-
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fected relatives throughout the genome. However, in no
single chromosomal region did the excess allele sharing
meet the criteria for statistical significance in a ge-
nomewide linkage scan. The regions with the highest Z
scores (on chromosomes 5, 12, and 19) need confir-
mation or refutation in other data sets. Conversely, the
present data fail to support strong roles for the loci
identified by other investigators. This failure is consis-
tent with the general lack of confirmation of rather
strong initial linkage signals that has plagued the study
of inherited susceptibility to prostate cancer. The
strength of these initial signals suggests that some rather
penetrant mutations are segregating in some families
and that the studies reporting signals have ascertained
by chance, a substantial fraction of such families.
The probable multiplicity of prostate cancer–sus-
ceptibility genes, their probably varied modes of inher-
itance, and their low penetrances complicate the task
of gene identification. An additional complication is the
variability within and between families in prostate can-
cer aggressiveness, as measured by the stage and grade
of disease at diagnosis. This variability has been in-
creased by the introduction of prostate-specific antigen
(PSA) screening in the mid-1980s. If a gene causes only
aggressive cancer and if PSA-detected prostate cancers
tend to be less aggressive, then the presence of PSA-
screened cancers in families studied for linkage could
substantially decrease power. These complications,
when coupled with other barriers to research in prostate
cancer etiology (e.g., the high prevalence of subclinical
cancer in older men) provide formidable challenges to
our further progress in attempts to understand the ge-
netic basis of this disease. A full discussion of these
issues and of suggested strategies for dealing with them
has recently been provided by Ostrander and Stanford
(2000).
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